CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced financial and operational results for the quarter ended March 31, 2015.
“We continue to advance our pipeline of rare disease and oncology programs, most recently with the announcement of robust non-human primate data using our conjugate platform for subcutaneous delivery of RNAi therapeutics,” stated Douglas M. Fambrough, Ph.D., Dicerna’s chief executive officer.
Help employers find you! Check out all the jobs and post your resume.
